SCHEMBL489135

SCHEMBL489135

CCC(O)OCC(O)COC(O)CC

nearest known ligand 0.50

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27320102 0.92 TSHR (0.48) TSHRKDM4E
SCHEMBL888322 0.87 TSHR (0.43) TSHRKDM4E
SCHEMBL27933045 0.81 TSHR (0.39) TSHR
SCHEMBL296902 0.80
SCHEMBL6144674 0.80
SCHEMBL1835824 0.77 TSHR (0.36) TSHRKDM4E
SCHEMBL2132847 0.76 TSHR (0.43) TSHR
SCHEMBL27796298 0.76
SCHEMBL62770 0.75
SCHEMBL1829740 0.74 TDP1 (0.41) TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9243050-B2 Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 Idera Pharamaceuticals, Inc. (US) 2016-01-26 US claimed
EP-2021008-B1 STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 IDERA PHARMACEUTICALS INC (US) 2015-12-02 EP claimed
US-20140308300-A1 STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 NOVAQUEST CO-INVESTMENT FUND XV, L.P. 2014-10-16 US claimed
US-8853375-B2 Toll like receptor modulators IDERA PHARMACEUTICALS, INC. (US) 2014-10-07 US claimed
US-8759310-B2 Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 IDERA PHARMACEUTICALS, INC. (US) 2014-06-24 US claimed
US-20130202584-A1 STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 IDERA PHARMACEUTICALS, INC. 2013-08-08 US claimed
EP-2179061-B1 TOLL LIKE RECEPTOR MODULATORS IDERA PHARMACEUTICALS INC (US) 2012-10-03 EP claimed
US-8106173-B2 Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 IDERA PHARMACEUTICALS, INC. (US) 2012-01-31 US claimed
US-20090053148-A1 TOLL LIKE RECEPTOR MODULATORS IDERA PHARMACEUTICALS, INC. 2009-02-26 US claimed
US-20080171712-A1 At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators IDERA PHARMACEUTICALS, INC. 2008-07-17 US claimed
EP-2021008-B1 STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 IDERA PHARMACEUTICALS INC (US) 2015-12-02 EP disclosed
US-RE28737-E Process for synthesizing specific complete mixed polyol esters THE PROCTER & GAMBLE COMPANY (US) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171712-A1 At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators TLR8, TLR7, TLR9 TSHR 1931/4885KDM4E 2326/4885
US-20130202584-A1 STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 TLR8, TLR7, TLR9 TSHR 572/4885KDM4E 945/4885
US-20140308300-A1 STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 TLR8, TLR7, TLR9 TSHR 572/4885KDM4E 945/4885
US-20090053148-A1 TOLL LIKE RECEPTOR MODULATORS TLR9, TLR3, TLR5 TSHR 943/4885KDM4E 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.